
UB864
ProductDapagliflozin Tablets
Strength5mg, 10mg
IndicationsType 2 diabetes mellitus; Chronic kidney disease
TherapeuticsMetabolic & Endocrinology
GMPUS - FDA
RegistrationUnited States
ModalitiesSmall Molecule
Exclusive Summary
- Backed by US-FDA GMP certification and US ANDA registration, providing top-tier quality endorsement to enable fast-track regulatory approvals globally.
- Covers three massive indications (T2DM, Heart Failure, CKD) addressing a global patient pool exceeding 1 billion, guaranteeing explosive and sustained market demand.
- Flawless timing to capitalize on the global patent cliff; combined with highly cost-effective Chinese manufacturing, it is an ideal asset for winning national tenders and rapid market penetration.
我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →